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Abstract  36 
The structure-specific nuclease human flap endonuclease-1 (hFEN1) plays a key role in DNA 37 
replication and repair and may be of interest as an oncology target. We present the first crystal 38 
structure of inhibitor-bound hFEN1 and show a cyclic N-hydroxyurea bound in the active site 39 
coordinated to two magnesium ions. Three such compounds had similar IC50 values but 40 
differed subtly in mode of action. One had comparable affinity for protein and protein–41 
substrate complex and prevented reaction by binding to active site catalytic metal ions, 42 
blocking the unpairing of substrate DNA necessary for reaction. Other compounds were more 43 
competitive with substrate. Cellular thermal shift data showed engagement of both inhibitor 44 
types with hFEN1 in cells with activation of the DNA damage response evident upon 45 
treatment. However, cellular EC50s were significantly higher than in vitro inhibition constants 46 
and the implications of this for exploitation of hFEN1 as a drug target are discussed. 47 
 48 
  49 
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Introduction  50 
Flap endonuclease 1 (FEN1) is the prototypical member of the 5′-nuclease superfamily,1,2 51 
whose activities span a range of cellular pathways involved in DNA replication and genome 52 
maintenance.3,4 FEN1 is a structure-selective metallonuclease essential for Okazaki fragment 53 
maturation through efficient removal of 5′-flaps resulting from strand displacement during 54 
lagging-strand synthesis.5,6 This reaction produces nicked DNA suitable for ligation, thereby 55 
ensuring maintenance of genomic fidelity. FEN1 is also involved in long-patch base excision 56 
repair7-9 (LP-BER), amongst other pathways. 57 
 58 
Given its critical replicative function, it is not surprising that FEN1 overexpression is 59 
characterized in multiple cancer types10-13 such that it has been suggested as both a biomarker 60 
relating to prognosis and disease progression, and a potential therapeutic target. Target 61 
validation studies have focused either on chemosensitization14,15 or synthetic lethal 62 
interactions16-19 with established oncogenes. Synthetic lethality arises when loss of function of 63 
either gene of an interacting pair is not cytotoxic, but mutation or inhibition of both does 64 
cause cell death; hence, targeting interacting partners of mutated genes in cancer offers 65 
potential for selective killing of cancer cells. 66 
 67 
Therapeutic interest in FEN1 arises from its known synthetic lethal interactions with several 68 
genes frequently mutated in cancers.16,17,20 FEN1 inhibition selectively impairs proliferation of 69 
colon cancer cells deficient in Cdc4 and Mre11a,16,18 both frequently mutated in colorectal 70 
cancers. FEN1 has also emerged as a potential chemosensitizing target due to its role in LP-71 
BER17 since it is critical for repair of MMS (methyl methanesulfonate)-induced alkylation 72 
damage,21 and its knockdown or inhibition increases sensitivity to TMZ (temozolomide) in 73 
glioblastoma13 and colorectal cancer14,16,18 cell lines.  74 
 75 
This considerable interest in human FEN1 (hFEN1) as a drug target has prompted 76 
development of high-throughput screening procedures22,23 and the discovery of an N-77 
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hydroxyurea based series of hFEN1 inhibitors.24 We investigated the specificity and mode of 78 
action of these compounds and found they prevented access of the scissile phosphate diester 79 
of substrate DNA to catalytic metal ions. We also demonstrated cellular activity and target 80 
engagement in live cells, leading to activation of the DNA damage response and apoptosis. 81 
 82 
Results  83 
N-Hydroxyurea hFEN1 inhibitors bind catalytic site metals  84 
Inhibitor 124 (Figure 1a) was co-crystallized with hFEN1–Mg2+ truncated after residue 336 85 
(hFEN1-336Δ), which retains all catalytic features but lacks the flexible 44 amino acid 86 
C-terminus.25,26 The crystal structure of the hFEN1-336Δ–inhibitor complex (Figure 1b) was 87 
solved at 2.84 Å resolution (Supplementary Results, Supplementary Table 1 and 88 
Supplementary Figure 1; PDB ID 5FV7) and resembled a kidney bean with the active site and 89 
requisite divalent metal ions residing at the indentation. The structure in the presence of the 90 
active site-bound inhibitor closely resembled that of hFEN1 in complex with proliferating cell 91 
nuclear antigen (PCNA).27 As with the PCNA-bound structure, no density was observed for 92 
the helical arch (α4 and α5) and α2-α3 loop regions, which are visible when co-crystallized 93 
with substrate or product DNA.2  94 
 95 
The inhibitor was situated in the protein’s nuclease active site with the N-hydroxyurea moiety 96 
directly coordinating two Mg2+ ions positioned 4.5 Å apart (Figure 1b), anchored by inner-97 
sphere metal-coordinating contacts from carboxylates of E160, D179 and D181 and outer-98 
sphere or water-mediated contacts from D34, D86, E158 and D233 (Figure 1c). The 99 
thiophene ring of the inhibitor filled a small hydrophobic pocket formed by M37, Y40 and 100 
V133, and the sulfur of M37 exhibited a short-distance (4Å) favorable contact to the electron 101 
deficient pyrimidine-2,4-dione ring of the ligand. The 2,3-dihydrobenzo[b][1,4]dioxine 102 
sidechain contacted M37 and Y40, though these contacts were less directional and mostly 103 
hydrophobic in nature. It was evident that different binding poses in the active site are 104 
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possible for the N-hydroxyurea series of inhibitors, which goes some way to rationalizing the 105 
reported SAR.24 The relatively weak nature of protein contacts with the sidechain (N1-106 
substituent) explained the modest improvement in IC50 values seen for compounds modified 107 
at this position.24 It is also understandable how substitutions restricting the conformational 108 
freedom of the sidechain—for example, introduction of a methyl group at the 7-position of 109 
the thieno[3,2-d]pyrimidine-2,4-dione system of 1—would significantly reduce binding 110 
affinity and therefore increase IC50, as is reported.24 111 
 112 
Inhibitor binding pose suggests a possible mode-of-action 113 
Coordination of 1 to the metal ions that catalyze specific phosphodiester hydrolysis of the 114 
substrate suggested a mode of action for this inhibitor. We modelled ternary protein–115 
inhibitor–DNA complexes using the present hFEN1-336Δ–inhibitor structure together with 116 
the published hFEN1-336Δ–product DNA complex2 (Figure 1d). Alignment of product-bound 117 
and ligand-bound structures indicated that the inhibitor and the phosphate monoester of the 118 
product DNA strand both co-locate to bind the metal ions. Conversely, in the hFEN1-336Δ–119 
substrate DNA complex2, the scissile bond is not in contact with active site metal ions 120 
because the DNA is base-paired. It is assumed a pre-reactive complex forms initially that 121 
requires the end of the DNA duplex to unpair and bind to metal ions as a prerequisite for 122 
cleavage.1,2,28 Hence, it was considered plausible that substrate could bind in the presence of 123 
inhibitor, but that this prevents DNA from accessing the catalytic metals as required for 124 
hydrolysis to occur (Figure 2a). An alternative hypothesis was that the inhibitor precludes 125 
DNA binding, although the compound was bound far from the other two main areas of 126 
protein–DNA interaction (K+/H2TH motif and 3′-flap binding pocket). We undertook further 127 
work to characterize the hFEN1-inhibitor interaction and establish whether the N-hydroxyurea 128 
inhibitors compete with substrate DNA binding.  129 
 130 
 131 
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Inhibitor binding to hFEN1 requires magnesium ions  132 
We quantified the interaction of 1, and related analogs 2 and 322 bearing a smaller or no 133 
sidechain (Figure 1a), with the substrate-free protein using isothermal titration calorimetry 134 
(ITC; Supplementary Table 2). Similar dissociation constants (KD) were obtained for 1 and 2 135 
in the presence of Mg2+ with either hFEN1-336Δ (Supplementary Figure 2) or full-length 136 
hFEN1 (Supplementary Figure 3a,b) but the KD of 3 was approximately 10-fold higher, 137 
suggesting interactions between the sidechains of 1 and 2 and the protein contribute to 138 
binding.  139 
 140 
Ca2+ ions are often employed as a nonviable cofactor in biophysical measurements with 141 
hFEN1 because they facilitate accommodation of the substrate DNA and its required 142 
conformational changes,28,29 but do not support catalysis. In fact, Ca2+ ions are a competitive 143 
inhibitor of 5′-nuclease reactions with respect to Mg2+,30,31 implying both ions occupy similar 144 
sites on the protein. However, KD values were drastically increased on replacement of Mg2+ 145 
with Ca2+ (Supplementary Figure 4), showing the latter did not support inhibitor binding. 146 
Thus, in accord with the crystal structure, interaction of 1 and 2 with hFEN1 was specific to 147 
the nuclease core domain and required Mg2+. To provide an estimate of residence time, we 148 
probed the interaction of 1 with hFEN1-336Δ using surface plasmon resonance 149 
(Supplementary Figure 2d) and obtained a dissociation constant similar to ITC with a 150 
residence time of 3 min. 151 
 152 
Inhibitors bind to both protein and protein–DNA complex 153 
Kinetic experiments were used to characterize hFEN1 inhibition by 1, 2 and 4. We measured 154 
rates of hFEN1-336Δ-catalyzed reaction with an optimal endonucleolytic double-flap 155 
substrate bearing a 5′-fluorescein label32 (DF1; Figure 2a, and Supplementary Figure 5a). At 156 
substrate concentration close to KM (100 nM), IC50 values for all three compounds were 157 
similar (Table 1), and a related exonucleolytic substrate gave similar IC50 results 158 
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(Supplementary Figure 6a,b). Mode of inhibition was determined by globally fitting rates of 159 
reaction at varying inhibitor and double-flap substrate concentrations to four inhibition 160 
models: competitive, uncompetitive, non-competitive and mixed inhibition.  161 
 162 
The uncompetitive model—where the inhibitor can only bind to enzyme–substrate complex—163 
afforded a poor fit for 1, which was unsurprising given the compound’s high affinity for free 164 
protein. The competitive model, where binding of inhibitor and substrate are mutually 165 
exclusive, also proved unsuitable but the mixed and non-competitive models produced 166 
acceptable fits (Figure 2b-d and Supplementary Figure 7). These models both assume the 167 
inhibitor can bind to DNA-free and DNA-bound forms of the enzyme, but the non-168 
competitive model (Equation 4) assumes both complexes have equivalent ligand dissociation 169 
constants. Allowing dissociation constants to vary (mixed inhibition; Figure 2b and Equation 170 
5) produced a marginally better data fit, yielding near-equivalent dissociation constants for 1 171 
(Table 1). Statistical model selection using Aikake’s Information Criteria (AIC) 172 
overwhelmingly preferred the mixed inhibition model.  173 
 174 
With compound 2, only the competitive (Equation 3) and mixed inhibition models produced 175 
acceptable fits (Figures 2e, S8). The same statistical criteria (AIC) again favored the mixed 176 
model, but in this case the derived dissociation constants (Kic and Kiu) varied by an order of 177 
magnitude (Table 1). For compound 4, only the competitive model produced an acceptable fit 178 
(Figure 2f, Table 1 and Supplementary Figure 9). Thus, whereas 1, 2 and 4 all bound to 179 
hFEN1–Mg2+ with similar efficiency, only 1 showed notable affinity for the enzyme-substrate 180 
complex (hFEN1–Mg2+–DNA), binding both DNA-free and DNA-bound forms of the 181 
enzyme with comparable dissociation constants. 182 
 183 
Evidence for an hFEN1–Mg2+–Inhibitor–DNA complex 184 
To verify formation of a quaternary complex of enzyme–Mg2+–inhibitor–DNA (E–Mg2+–I–185 
DNA), we tested the ability of E–Mg2+–I to form complexes with DNA without significant 186 
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hydrolysis of the substrate occurring. High concentrations of 1 or 2 (100 μM) slowed the rate 187 
of Mg2+-catalyzed reaction 10,000-fold under single-turnover conditions (Table 1 and 188 
Supplementary Figure 10), but appreciable substrate cleavage was still seen over the 189 
timescale required for biophysical measurements. Because Ca2+ did not support inhibitor 190 
binding (Supplementary Figure 4), substituting it in place of Mg2+ as a nonviable cofactor was 191 
not applicable. Instead, we employed a previously characterized hFEN1 mutant, R100A. 192 
Arg100 is strictly conserved in FEN1 proteins and its mutation to alanine slows reaction 193 
7,000-fold.33 The half-life of substrate with R100A–Mg2+ and inhibitors was sufficiently long 194 
to permit measurements without significant product formation (Supplementary Figure 9), and 195 
ITC confirmed the mutation did not affect inhibitor binding (Supplementary Table 2).  196 
 197 
Both 1 and 2 formed R100A–Mg2+–I–DNA complexes as demonstrated by increases in 198 
anisotropy (r) of DF1 substrate upon titration with R100A–Mg2+–I, with r reaching a common 199 
limiting value at high enzyme concentration (Figure 3a). Data fitting to a simple binding 200 
isotherm revealed similar trends in KD between R100A and its wt equivalent, with which the 201 
use of non-catalytic Ca2+ ions was necessary to prevent reaction (Supplementary Figures 11a-202 
d, 12a). Competing away bound, FAM-labeled substrate with its unlabeled equivalent 203 
demonstrated specific interaction between R100A and this substrate (Supplementary Figures 204 
5a,b, 11h). Substrate dissociation constants differed between quaternary complexes containing 205 
1 or 2 (Figure 3a): with compound 1, R100A–Mg2+–1 displayed a KD only threefold greater 206 
than that for R100A–Ca2+. In contrast, the substrate bound 10-fold more weakly to R100A–207 
Mg2+–2. These results were consistent with 1 having a closer Kiu value relative to Kic than 2, 208 
again suggesting 2 was more competitive than mixed in character. 209 
 210 
DNA is bent in complexes with or without inhibitors 211 
hFEN1 possesses two juxtaposed double-stranded DNA binding sites that accommodate 212 
double-flap substrate DNA in a conformation with a 100° bend at the junction. To ascertain 213 
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whether DNA bound similarly in the presence of inhibitor, we examined substrate bending 214 
using FRET. We labelled double-flap substrate with a rhodamine-fluorescein dye pair on its 215 
respective duplexes, and verified binding to hFEN1 produces an increase in FRET signal34 216 
(Figure 3b and Supplementary Figures 5c-f, 14). Titration of R100A–Ca2+ or R100A–Mg2+–1 217 
into the labeled substrate produced comparable FRET efficiency start and end values (Figure 218 
3b) confirming the enzyme had engaged both DNA binding sites with or without inhibitor. 219 
The substrate KD was raised by a factor of three in the presence of 1, whereas substrate 220 
binding was much weaker with 2 present (Figure 3b and Supplementary Table 3); hence, 221 
these results mirrored those obtained earlier by fluorescence anisotropy. 222 
 223 
Inhibitors bound to catalytic metals block DNA unpairing 224 
Unpairing of the reacting substrate duplex, which places the target phosphodiester onto active 225 
site metal ions, is a prerequisite for hFEN1-catalysed reaction one nucleotide into the double-226 
stranded DNA (Figure 2a).28 This metal ion-dependent conformational change may be 227 
monitored using substrates containing a tandem 2-aminopurine (2AP) exciton pair at the –1 228 
and –2 positions of the 5′-flap strand (DF3, Supplementary Figure 5g) by measuring changes 229 
in the low energy exciton-coupled CD spectrum resulting from the 2APs, usually in the 230 
presence of Ca2+ to prevent reaction.28 231 
 232 
In adopting the reactive conformation, the +1 and –1 nucleotides are assumed to become 233 
extrahelical whereas the –2 nucleotide remains base-paired. In the absence of active site 234 
divalent ions (EDTA added), a strong maximum at 330 nm is observed from the R100A–235 
DNA complex, due to the exciton pair and consistent with substrate remaining base-paired.28 236 
With R100A–Ca2+–DNA, the DNA conformational change reverses the sign of the CD signal 237 
producing a deep minimum at 310 nm (Figure 4a). In the presence of 1 or 2, the measured CD 238 
signal of R100A–Mg2+–I–DNA did not differ significantly from that observed for R100A–239 
DNA without divalent ions (Figure 4b,c), even though the DNA was assumed to be fully 240 
bound under these conditions (10 μM DNA, 12.5 μM R100A). This demonstrated that the 241 
10 
 
inhibitors prevented substrate conformational rearrangements necessary for hydrolysis 242 
(Supplementary Figure 15). 243 
 244 
N-Hydroxyurea FEN1 inhibitors also target EXO1 245 
FEN1 is the prototypical member of the structure-specific 5′-nuclease superfamily, also 246 
comprising exonuclease 1 (EXO1), gap endonuclease 1 (GEN1) and Xeroderma 247 
Pigmentosum complementation group G protein (XPG).1 Exoribonucleases XRN1 and 2 are 248 
also suggested members of the superfamily.1 These nucleases all share a similarly-folded 249 
nuclease domain with similar active site geometry and full conservation of essential catalytic 250 
residues.1,2 Consequently, it has been hypothesized that the substrate selectivity of these 251 
proteins stems from strict recognition of their respective DNA substrate structures, followed 252 
by double nucleotide unpairing to initiate scissile phosphate diester hydrolysis.1  253 
 254 
It is known that hFEN1 inhibitors can exhibit limited but manageable promiscuity towards 255 
XPG.24 However, testing against human EXO1-352Δ (nuclease domain of EXO1)35 revealed 256 
that compounds 1 and 2 both inhibited this target with IC50 values similar to those against 257 
hFEN1 (Supplementary Figures 5k, 6a,e). Differential scanning fluorimetry experiments36 258 
further confirmed binding of both compounds to both proteins in a divalent metal ion-259 
dependent manner (Supplementary Figure 6g,h). In contrast, inhibitor 1 was found ineffective 260 
against bacteriophage T5 FEN (Supplementary Figures 5l, 6c) and Kluyveromyces lactis 261 
XRN1 (Supplementary Figure 16), both of which show a high level of active site conservation 262 
with the mammalian 5′-nuclease superfamily.1 Similarily, 1 did not inhibit the structurally 263 
unrelated DNA repair metallonuclease APE1 (Supplementary Figure 6f). 264 
 265 
When hFEN1 acts in vivo it is usually associated with the toroidal clamp PCNA. PCNA 266 
increases the stability of FEN1–DNA complexes,34 suggesting that association with PCNA 267 
might allow FEN1 to overcome inhibition. However, when we added hPCNA to hFEN1 268 
reactions inhibited by 1 or 4, the slow rates of reaction observed did not increase implying the 269 
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FEN1 interaction partner does not dramatically influence the IC50 of either compound 270 
(Supplementary Figure 6d). 271 
 272 
N-Hydroxyurea inhibitors engage with hFEN1 in live cells 273 
On the basis of contrasting inhibition modes, compounds 1 and 4 were selected for additional 274 
cellular studies. We employed the cellular thermal shift assay technique (CETSA)37 to 275 
establish whether they interacted with hFEN1 in SW620 colon cancer cells. CETSA detects 276 
changes in stability of a protein upon engagement with a ligand, like a biochemical thermal 277 
shift assay, but is performed with whole cells and a target-specific, label-free readout of 278 
engagement is obtained using a relevant antibody. Compounds 1 and 4 stabilized hFEN1 279 
(Figure 5a-c and Supplementary Figure 17) with EC50 = 5.1 μM and 6.8 μM, respectively, in 280 
an isothermal concentration–response experiment, representing similar EC50s regardless of 281 
their differing modes of inhibition. Interestingly, these micromolar-range values represented a 282 
substantial drop-off in observed binding affinity compared with observations in prior 283 
biochemical assays (IC50 = 46 nM and 17 nM, respectively; Table 1) so we undertook a 284 
number of experiments to attempt to explain this. Cell permeability in MDCK and Caco-2 285 
assays was not an issue (Supplementary Table 4); neither were other properties including 286 
solubility and chemical stability. The compounds’ affinity for free divalent metal ions in 287 
solution was insignificant, ruling out metal chelation as an explanation. Nonspecific protein 288 
binding may have contributed to the discrepancy between biochemical and phenotypic 289 
potency, although binding to other 5′-nuclease superfamily members represented the most 290 
obvious potential for off-target effects. Hence, we attempted further CETSA studies with 1 291 
and 4 against hEXO1 but this was concluded to be a non-viable CETSA target (with only 292 
fragments of the protein detected on the blots), perhaps reflecting instability of the protein 293 
under the assay conditions, or its cellular context as a component of multi-protein complexes 294 
(which regulate its activity). 295 
 296 
 297 
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hFEN1 inhibition activates the DNA damage checkpoint 298 
High concentrations of compound 1 proved cytotoxic towards SW620 cells with an EC50 of 299 
11 μM (Figure 5d), but HeLa cells stably expressing hFEN1-shRNA were 70% viable at 20 300 
μM 1 (Figure 5e; purple curve). Mock-shRNA expressing HeLa cells were only 15% viable 301 
under the same conditions (Figure 5e; black curve), showing similar susceptibility to 1 as 302 
untransformed cells. Hence, a lack of hFEN1 conferred resistance to 1, suggesting on-target 303 
activity as the primary cause of cytotoxicity. SW620 cells also showed increased sensitivity to 304 
MMS when co-treated with 1, in a dose-dependent manner (Figure 5f), suggesting the 305 
compound inhibits the LP-BER function of FEN1 in a cellular context. Enhanced toxicity of 1 306 
towards HeLa cells expressing Rad54b-shRNA (Figure 5e; green curve) was also observed 307 
with an EC50 of 6.4 μM compared to 14.9 μM against untransformed cells (Figure 5e,g), 308 
confirming the synthetic lethal interaction between Fen1 and Rad54b previously 309 
demonstrated by silencing of the former.18 Inhibitor 4 also proved cytotoxic to HeLa cells 310 
(EC50 6 μM; Figure 5g), appearing more potent than 1, whose EC50 of approximately 15 μM 311 
was in line with its toxicity against SW620 cells. 312 
 313 
When treated with sub-lethal doses of 1, SW620 cells showed evidence of an induced DNA 314 
damage response (Figure 5h and Supplementary Figure 18) at concentrations consistent with 315 
the EC50 for target engagement observed by CETSA. The same compound effected a dose-316 
dependent increase in ubiquitination of FANCD2, a marker for activation of the Fanconi 317 
anemia pathway recruited to stabilize stalled replication forks.38-40 At higher doses, 318 
accumulation of phosphorylated ATM and γH2AX was evident, indicating accumulation of 319 
unrepaired DNA double-strand breaks (DSBs). Cells treated with high concentrations of 1 320 
also showed evidence of apoptosis, shown by the presence of cleaved PARP (Figure 5h). 321 
Knockdown of hFEN1 by siRNA activated a similar DNA damage response to treatment with 322 
1; these cells accumulated γH2AX but otherwise remained viable (Figure 5i and 323 
Supplementary Figure 19). DNA damage response activation and apoptosis were consistent 324 
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with loss of hFEN1 function, because the consequences of unprocessed Okazaki fragments 325 
would include stalled or collapsed replication forks, replication errors and double strand 326 
breaks.  327 
 328 
Discussion  329 
N-Hydroxyurea compounds 1, 2 and 4 prevented DNA cleavage with similar efficiency 330 
(Table 1), reflecting the SAR observed previously for similar-sized compounds24 inasmuch as 331 
comparable IC50 values were obtained despite notable differences in sidechain size and 332 
structure. These results were consistent with protein–inhibitor binding mediated primarily 333 
through interaction with active site Mg2+ ions, and a lack of strong contacts between the 334 
protein and inhibitor sidechain, as seen in the structure of 1 bound to hFEN1 (Figure 1 and 335 
Supplementary Table 2). Although the metal-coordinating headgroup clearly provided the 336 
predominant binding contribution, the elevated KD of 3 suggested interaction of the inhibitor 337 
sidechain with the protein was nonetheless important for optimal affinity. Further studies 338 
revealed subtle differences in mode of action on variation of the sidechain structure. 339 
 340 
Although the DNA substrate bound in its usual conformation in the presence of compound 1, 341 
hydrolysis was impaired by prevention of double nucleotide unpairing through steric blocking 342 
of the catalytic metals (Figures 1b-d, 3, 4). These observations were reminiscent of the action 343 
of the HIV integrase inhibitor raltegravir.41 Raltegravir and functionally related compounds 344 
bind to active site metal ions of the integrase–DNA complex, similarly obstructing access of 345 
the reacting phosphodiester bond to the metals. In contrast, compounds 2 and 4, with altered 346 
sidechains, proved mostly competitive in character and primarily acted to reduce affinity of 347 
the enzyme for its DNA substrate.  348 
 349 
The micromolar EC50s seen in CETSA experiments with 1 and 4 differed markedly from the 350 
compounds’ nanomolar potency against purified protein – though they were consistent with 351 
phenotypic potency in DNA damage induction and cytotoxicity assays. A clear explanation 352 
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for this was not found, but the raised cellular EC50s might reflect a high local concentration of 353 
hFEN1 in the nucleus during S-phase, which could conceivably reach the micromolar range. 354 
The residence time of compound 1 on hFEN1 proved similar to that of raltegravir on its target 355 
(4.8 min),42 although this is short compared to the median of 51 min for a representative set of 356 
marketed drugs,42 so the short residence time of 1 may necessitate a high local drug 357 
concentration in the vicinity of the target for effective inhibition in cells. 358 
 359 
Although hEXO1 is likely inhibited alongside hFEN1, the cellular concentration of hEXO1 is 360 
not expected to be significantly higher, so this seems an unlikely explanation for the raised 361 
EC50 values. The results with hFEN1-deficient cells (Figure 5e) did suggest some degree of 362 
target specificity, but previous cellular studies assuming selective inhibition of hFEN1 by the 363 
N-hydroxyurea series must nonetheless be interpreted with caution based on the likelihood of 364 
parallel hEXO1 inhibition, since it will not be possible to distinguish between phenotypes of 365 
hFEN1 and hEXO1 inhibition with this class of compounds. One such published24 inhibitor, 366 
related to 1-4, was employed to help validate a role for hFEN1 in homologous recombination 367 
(HR),43 demonstrating deficient HR upon treatment. However, hEXO1 is essential for 368 
competent HR,44-47 and the observed phenotype is explicable by inhibition of this enzyme 369 
alone. Although a role for hFEN1 in HR is otherwise supported in that study, we concluded 370 
that the N-hydroxyurea series should not be regarded as exclusive hFEN1 inhibitors. 371 
 372 
The mixed inhibition mode of 1, which in theory permits ‘dead-end’ complexes of DNA and 373 
protein to form, did not confer any advantageous inhibition characteristics in cells. 374 
Unprocessed Okazaki fragments resulting from hFEN1 inhibition might be successfully 375 
repaired by the cell with apoptosis only resulting when the DNA damage response is 376 
overwhelmed. Some support for this notion was seen in SW620 cells treated with 1, where we 377 
observed dose-dependent activation of the Fanconi anemia pathway (Figure 5h). Because 378 
FANCD2 is recruited to stabilize stalled replication forks and initiate repair,38 treatment with 379 
1 evidently did interrupt replication, prompting cells to activate other pathways to repair 380 
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unprocessed Okazaki fragments directly. Failure to achieve this may cause collapse of 381 
replication forks into DSBs, and at higher doses of compound 1, we did see evidence for DSB 382 
repair pathway activation. These markers did not accumulate at lower doses, so the damage 383 
signal may only be obvious when the frequency of DSBs overwhelms the cell’s DNA damage 384 
response. Accumulation of cleaved PARP, indicating early apoptosis, also suggested cells 385 
exposed to 1 were accumulating DNA damage associated with hFEN1 and/or hEXO1 386 
inhibition and signaling for apoptosis.  387 
 388 
Without exposure to inhibitor, both SW620 cells treated with hFEN1-siRNA and HeLa cells 389 
stably expressing hFEN1-shRNA showed viability indistinguishable from untransformed 390 
controls yet constitutively initiated a DNA damage response (Figure 5i). The hFEN1-shRNA 391 
cells showed reduced sensitivity to 1, suggesting a degree of selectivity and on-target activity 392 
for the compound since the DNA damage reponse remained competent. Our data suggests 393 
removal of functional hFEN1 alone did not induce toxicity and that damage associated with 394 
its loss is successfully repaired until such mechanisms become overwhelmed. This result, 395 
alongside our other observations in human cells, suggests targeting of hFEN1 in cancer will 396 
not prove effective as a monotherapy, but could be useful in exploiting synthetic lethal 397 
vulnerabilities. Synthetic lethal interactions between hFEN1 and Rad54b,18 Cdc416 and 398 
Mre11a16 are established, and other such interactions with potential clinical relevance are 399 
proposed.16,38 We confirmed synthetic lethal interaction with Rad54b, previously established 400 
using hFEN1 knockdown,18 through inhibition of the latter by 1. Thus, hFEN1 inhibitors 401 
might prove beneficial as a component of targeted or personalized therapies, provided 402 
selectivity over hEXO1 and the other 5′-endonuclease superfamily members can be realized. 403 
 404 
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The PDB accession code for the crystal structure presented in Figure 1 is 5FV7. 406 
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Figure Legends 554 
Figure 1. Compounds used in this study and crystal structure of hFEN1-336Δ in 555 
complex with compound 1. (a) Schematic illustration of compounds 1–4 that are inhibitors 556 
of hFEN1 phosphate diester hydrolysis. (b) Structure of hFEN1-336Δ nuclease active site 557 
(PDB ID 5FV7) showing the seven highly-conserved acidic residues (grey and red spheres 558 
represent carbonyl carbon and oxygen atoms, respectively), the two bound magnesium ions 559 
(pink spheres), and compound 1. (c) Schematic representation of the metal-coordination 560 
spheres of the two active site magnesium ions with distances reported in Ångstrom. (d) 561 
Structure of hFEN1-336Δ in complex with product DNA (PDB ID 3Q8K) superimposed with 562 
the hFEN1-336Δ in complex with compound 1 (protein not shown) to show that the inhibitor 563 
and terminal nucleotide of the product DNA interact with the divalent magnesium ions and 564 
share same pocket created by the protein. Metals are shown as pink spheres, terminal 5′ 565 
nucleotide (–1) highlighted in cyan box, penultimate nucleotide of the product DNA (–2) 566 
highlighted in the pink box, and compound 1 highlighted in the green box.  567 
 568 
Figure 2. Differences in inhibition characteristics of the compounds. (a) hFEN1-catalyzed 569 
reaction schematic showing double nucleotide unpairing at positions +1 and –1 (numbering 570 
relative to scissile phosphate). (b,c) Reaction schemes of mixed inhibition (b) and competitive 571 
inhibition (c) models. In each case, E, S, I and P represent enzyme, substrate, inhibitor and 572 
product, respectively. Kic is the dissociation constant of I from free enzyme (competitive with 573 
substrate) and Kiu is the dissociation constant of I from ES complex (uncompetitive). (d–f) 574 
Nonlinear regression plots of normalized initial rates of reaction vs. substrate concentration 575 
(open diamonds) for substrate DF1 at varying concentrations of compounds 1 (d; inset shows 576 
equation for mixed inhibition model), 2 (e; inset shows legend correlating color/symbol to 577 
inhibitor concentration) and 4 (f; inset shows equation for competitive inhibition model). 578 
Error bars represent standard errors from global fitting of combined data from two triplicate 579 
experiments (fits to alternative models are shown in Supplementary Figures S7–S9). 580 
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 581 
Figure 3: Effect of inhibitors on substrate binding assessed by fluorescence anisotropy 582 
(FA) and FRET. (a) Typical FA titration data for hFEN1-R100A binding DF1 in the 583 
presence of 10 mM Ca2+ (magenta, open triangles), 8 mM Mg2+ plus 100 μM compound 1 584 
(blue, open circles) or 8 mM Mg2+ with 100 μM compound 2 (green, open squares); three 585 
independent titrations were carried out for all FA binding experiments. (b) Representative 586 
curves of typical normalized FRET binding data for DF1 and hFEN1-R100A. Experiments 587 
were conducted in triplicate, but only one data set and curve is shown here for each titration. 588 
Colours and symbols for each of the three plots are the same as in panel (a). 589 
 590 
Figure 4: N-Hydroxyurea inhibitors prevent FEN1 reaction by blocking substrate 591 
unpairing. CD spectra recorded at pH 7.5 and 20 °C of (a) tandem 2-aminopurine containing 592 
substrate DF3 (illustrated schematically as inset, and Supplementary Figure 5g) alone in the 593 
presence of 10 mM Ca2+ (blue) or 25 mM EDTA (grey) and the same substrate bound to 594 
hFEN1-R100A in the presence of 10 mM Ca2+ (magenta) or 25 mM EDTA (green); (b) DF3 595 
bound to hFEN1-R100A in the presence of Mg2+ plus excess compound 1 (cyan) or EDTA 596 
plus excess compound 1 (red); (c) DF3 bound to hFEN1-R100A with excess compound 2 in 597 
the presence of Mg2+ (orange) or EDTA (purple). Full DNA sequences are shown in 598 
Supplementary Tables 5,6 and Supplementary Figure 5g. Plots in panels a–c are 599 
representative of experiments repeated independently three times. 600 
 601 
Figure 5. Cellular engagement and activity of hFEN1 inhibitors 1 and 4. (a) 602 
Representative data of Western blot intensities from a melt curve for compound 1 ((+) 603 
indicates treated sample, (–) indicates control sample). (b) Melt and shift curve of FEN1 in 604 
intact SW620 cells with 100 μM 1 (purple), 4 (orange) and DMSO (control, black). (c) Ratio 605 
of hFEN1 protein isothermal shifts in cells with respect to concentration of compounds 1 606 
(purple) or 4 (orange) after exposure of cells to 50 °C to indicate magnitude of target 607 
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engagement of FEN1 in intact treated SW620 cells. (d) Dose-dependent sensitivity of SW620 608 
cells to compound 1. (e) Sensitivity of HeLa cells stably expressing Fen1 (orange), Rad54b 609 
(green) or non-targeting (black) shRNA to compound 1. (f) MMS sensitivity of SW620 cells 610 
treated with continuous dose of 10 μM compound 1 (purple) or DMSO (control, black). (g) 611 
Dose-dependent sensitivity of HeLa cells to compounds 1 and 4. (h) Typical Western blots 612 
showing 1 induces a DNA damage response in a dose-dependent manner. (i) SW620 cells are 613 
insensitive to deletion of FEN1 by siRNA, but accumulate DNA damage. Panels (b) and (c) 614 
show data from three independent triplicate experiments, fitted globally (i.e. N = 3, n = 9) 615 
with standard error. Panels (d)–(g) and (i) show the mean of three independent experiments ± 616 
standard error. 617 
  618 
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Tables 619 
Table 1. Kinetic parameters in absence and presence of inhibitors. 620 
 621 
 622 
§IC50 values derived from rates at substrate concentration close to KM (100 nM). kSTmax is 623 
maximal reaction rate under single turnover conditions, used to calculate the substrate half-624 
life (t1/2). ΔAICc is the difference between second order (corrected) Akaike Information 625 
Criteria values between models; if ≥6, the likelihood the incorrect model was selected is P < 626 
0.0001. ΔAICc for 1* and 2¶ compares non-competitive with mixed-inhibition models and 627 
competitive with mixed-inhibition models, respectively. Mixed-inhibition is preferred for 628 
both. For 4, competitive inhibition was the only model whose fit was not ambiguous (Amb.). 629 
 630 
  631 
Enzyme Inhibitor IC50, nM§ kcat, min-1 KM, nM Kic, nM Kiu, nM kSTmax, min–1 t1/2, min ΔAICc 
hFEN1 None n.a. 165±9 20±3 n.a. n.a. 916±49 7.57×10–4 n.a. 
hFEN1 1 n.d. n.d. n.d. n.d. n.d. 0.48±0.04 1.43 n.a. 
hFEN1 2 n.d. n.d. n.d. n.d. n.d. 1.52±0.09 0.46 n.a. 
hFEN1-336Δ None n.a. 160±10 151±16 n.a. n.a. 755±35 8.94×10–4 n.a. 
hFEN1-336Δ 1 46.4±4.8 140±9 297±31 48±5 117±27 n.d. n.d. 24.76* 
hFEN1-336Δ 2 30.0±6.0 182±13 422±50 17±2 306±125 n.d. n.d. 10.21¶ 
hFEN1-R100A None  n.a. n.d. n.d. n.d. n.d. 0.087±0.003 7.94 n.a. 
hFEN1-R100A 1 n.d. n.d. n.d. n.d. n.d. ~4×10-4  ≤1750 n.a. 
hFEN1-R100A 2 n.d. n.d. n.d. n.d. n.d. ~2×10-3 ≤360 n.a. 
hFEN1-336Δ 4 16.9±1.2 194.5±11 630.8±53 26±2 n.a. n.d. n.d. Amb. 
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 632 
Online Methods 633 
Protein Expression and Purification  634 
hFEN1-Wild-type hFEN1 and the mutant hFEN1 protein, R100A, were expressed from 635 
previously-prepared pET28b vectors containing the appropriate sequences for WT or R100A 636 
and subsequently purified and stored as described previously.2 The C-terminally truncated 637 
counterparts of wt-hFEN1 and R100A (i.e. hFEN1-Δ336 and R100A-Δ336 respectively) were 638 
expressed from previously-prepared pET29b vectors containing the respective hFEN1-336 639 
sequence in-frame with a PreScission protease site and (His)6-tag after residue 336 (removing 640 
44 residues). The proteins were then purified and stored as previously described.2 T5FEN 641 
protein was expressed and purified as previously described.29 642 
 643 
hEXO1-To create a vector for the expression of truncated, wild-type hEXO1-352 bearing an 644 
in-frame TEV protease site and C-terminal (His)6-tag, primers (5'-645 
gtctctcccatggggatacagggattgctac-3' and 5'-ggttctccccagctcttgaatgggcaggcatagc-3')—to amplify 646 
hEXO1-352 DNA bearing leader sequences necessary for ligation independent cloning (LIC) 647 
with SmaI-digested pMCSG28 vector (DNASU plasmid repository)—were utilized according 648 
to protocol.48 The DNA sequence encoding hEXO1-352-TEV-(His)6-Stop was then subcloned 649 
from the pMCSG28-hEXO1-352 vector into a pET21a vector using the NdeI and NotI 650 
restriction sites with appropriate primers (5'-ggaattccatatggggatacagggattgctac-3' and 5'-651 
ggataagaatgcggccgcttaatgatgatgatggtggtgcc-3'). The hEXO1-352-TEV-(His)6 protein was 652 
expressed in BL21(DE3)-RIPL E. coli using autoinduction media as described. The protein 653 
was purified by Co2+-immobilized affinity and anion exchange chromatography in a manner 654 
analogous to that described previously for hFEN1.2 Fractions containing hEXO1-352-TEV-655 
(His)6 were pooled, concentrated using an Amicon ultrafiltration device with a 5,000 MWCO 656 
membrane and then dialyzed into 2X 2L 50 mM Tris pH 7.0, 50 mM NaCl, 5 mM DTT, 1 657 
mM EDTA, 5% glycerol containing 1000U of TurboTEV (BioVision) to remove the (His)6-658 
tag. The dialysate was treated with MagneGST™ glutathione particles to remove the 659 
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TurboTEV, and then the protein was further purified using a Heparin affinity column and a 660 
salt gradient from 0 to 1 M NaCl as described previously.35 hEXO1-352-containing fractions 661 
were pooled, concentrated by ultrafiltration as before and then applied to a 16/60 Sephacryl™ 662 
S-100 HR (GE Lifesciences) column. Fractions containing the protein were concentrated and 663 
finally stored at 100 µM at –20 °C in 50 mM Tris pH 8.0, 50 mM NaCl, 1 mM DTT, 50 μM 664 
EDTA, 50% v/v glycerol. 665 
 666 
PCNA-The vector for human PCNA sub-cloned in-frame with a C-terminal-(His)8-tag into 667 
pET41b using the NdeI and XhoI restricition sites was a kind gift of Professor Binghui Shen 668 
(Beckman Research Institute, City of Hope). The hPCNA-(His)8 protein was expressed 669 
overnight at 37 °C in BL21(DE3)-RIPL E. coli using autoinduction media as described.49 The 670 
cells were collected by centrifugation at 6000 g and resuspended in ice-cold PBS buffer. The 671 
cells were pelleted again and the supernatant was removed. The cell pellet was resuspended in 672 
Buffer A (25 mM Tris pH=7.4, 0.02% NaN3, 5 mM imidazole, 2 mM β-mercaptoethanol) 673 
containing 1M NaCl, 1X EDTA-free protease inhibitor cocktail, and 0.1 mg/mL lysozyme. 674 
After cell lysis by freeze thaw and sonication, Buffer A containing 1% Tween-20 (10% of the 675 
total volume of the lysate) was added. The lysate was clarified by centrifugation at 30,000 g 676 
for 30 minutes at 4 °C. The supernatant was then applied to Co2+-TALON immobilized 677 
affinity column and washed with 5 column volumes of Buffer A. The column was then 678 
washed with 5 CV of Buffer A containing, 200 mM NaCl, and 0.01% NP-40. The protein was 679 
then eluted in buffer B (25 mM Tris pH=7.4, 0.02% NaN3, 200 mM NaC,l 250 mM 680 
imidazole, 2 mM β-mercaptoethanol, 0.01% NP-40%). The eluate was directly applied to two 681 
tandem 5 mL Hi-Trap Q columns and further purified as described.50 Briefly, the fractions 682 
containing hPCNA were pooled and dialysed 2 X 2L into Buffer C (25 mM KPO4 pH=7.0, 683 
0.01% NP-40%, 10% glycerol, 10 mM NaHSO3, 5 mM DTT, 0.02% NaN3). The dialysate 684 
was passed through a 5 mL Hi-Trap S HP column that was pre-equilibrated with Buffer C to 685 
remove impurities, but hPCNA was found exclusively in the flow-through. The flow-through 686 
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was loaded onto a hydroxylapatite column (BioSepra HA Ultrogel, 11 cm by 2.6 cm) and then 687 
eluted using a 20-column volume gradient from 0.025 and 0.5 M KPO4 in Buffer C. The 688 
eluate was dialysed 2 X 2Lt into Buffer D (25 mM potassium phosphate pH 7.0, 1.5 M 689 
(NH4)2SO4, 0.02% NaN3). The dialysate was centrifuged at 3,300 g for 10 minutes at 4 °C to 690 
remove any precipitate and then loaded onto a HiPrep Phenyl-Sepharose FF (high sub) 691 
column and eluted using a 20 column volume inverse gradient using Buffer D and Buffer E 692 
(25 mM potassium phosphate pH 7.0, 10% glycverol, 0.02% NaN3). The isolated PCNA was 693 
then dialysed into Buffer F (100 mM HEPES pH=7.5, 200 mM KCl, 10 mM DTT, 0.1 mM 694 
EDTA, 0.04% NaN3), and concentrated to provide 200 μM PCNA trimer (i.e. 600 μM 695 
monomer) before the addition of glycerol to 50% v/v and storage at –20 °C.  696 
 697 
KlXRN1-The vector corresponding to residues 1–1245 of Kluyveromyces lactis Xrn1 that was 698 
subcloned in-frame with a C-terminal hexahistidine tag into pET-26b was a kind gift of 699 
Professor Liang Tong laboratory (Columbia University). The protein was expressed in 700 
Rosetta E.coli according to protocol51 and purified as described for hFEN1. Once purified, the 701 
protein was stored in 20 mM Tris pH = 7.5, 200 mM NaCl, 2 mM DTT and 50% glycerol. 702 
The purity of all proteins used was assessed by SDS-PAGE (Supplementary Figure 20). 703 
 704 
Crystallisation and Structure Determination – The C-terminally truncated protein was 705 
crystallized using the hanging drop vapor diffusion method. Briefly, the protein was 706 
concentrated to approximately 8 mg/mL in a buffer containing 50 mM Tris pH 7.5, 200 mM 707 
NaCl, 10 mM MgCl2, 1 mM TCEP with 5 mM inhibitor 1 added. The crystallization well 708 
contained 25% PEG 3350, 0.1 M MOPS pH 7.0, 5% 2-propanol and 2% glycerol. Crystals 709 
appeared after 3 days at room temperature. Data were collected at the ERSF synchrotron on 710 
station ID23 (T = 100 K). Data were processed and scaled using the XDS and SCALA 711 
software packages.52 The crystals diffracted to 2.8 Å resolution, belong to Space Group P1 712 
and having unit cell dimensions of a = 43.3Å, b = 50.2 Å, c = 66.9 Å, α = 102.1°, β = 94.0°, 713 
γ = 90.7°. The structure was solved by molecular replacement, model rebuilding was 714 
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conducted using COOT53 and the structure was refined using the BUSTER software.54 The 715 
final model has good geometry with 92% of residues in the favored region of the 716 
Ramachandran plot, 7% in the allowed regions and 1% in the disallowed regions as defined 717 
by PROCHECK.52 At convergence a final crystallographic R-factor of 23.3% was achieved.  718 
Full data and refinement statistics are shown in Supplementary Table 1 and ligand electron 719 
density in Supplementary Figure 1.  720 
 721 
Isothermal Titration Calorimetry (ITC) – Binding affinities of wt hFEN1, hFEN1-336Δ and 722 
hFEN1-R100A for compounds 1 and 2 were measured using either a VP-ITC 723 
microcalorimeter (GE Healthcare) or NANO-ITC (TA Instruments). The appropriate protein 724 
was exchanged from storage buffer into 100 mM KCl, 1 mM DTT, 50 mM HEPES pH 7.5 725 
containing 8 mM MgCl2 or 10 mM CaCl2 using a HiPrep 26/10 desalting column at 4 °C. 726 
Subsequently, the protein was dialyzed overnight at 4 °C against the same buffer composition.  727 
In all cases, the dialysate was used prepare a solution with final protein concentration 18 μM 728 
(based on A280 using extinction coefficients calculated using the ExPASy ProtParam tool, 729 
http://web.expasy.org/protparam/) and final inhibitor concentration 200 μM, diluted from 730 
DMSO stock solution to a final DMSO concentration of 1%. Twenty-five injections were 731 
performed with 180 s spacing time at 25 °C. Titration traces were integrated by NITPIC55 and 732 
the resultant curves were globally fit by SEDFIT.56 The figures were prepared using GUSSI 733 
(http://biophysics.swmed.edu/MBR/software.html). 734 
 735 
Synthesis and Purification of DNA constructs – The DNA oligonucleotides detailed in 736 
Supplementary Table 5, including those synthesised with 5′-fluorescein-CE-phosphoramidite 737 
(6-FAM), internal dSpacer-CE-phosphoramidite (dS) or containing site-specific 2-738 
aminopurine (2AP) substitutions, were purchased with HPLC purification from DNA 739 
Technology A/S (Risskov, Denmark). MALDI–TOF spectrometry confirmed experimental 740 
molecular weights were all within 3 Da of calculated values (data not shown). The 741 
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concentration of individual oligonucleotides was determined by measuring the absorbance at 742 
260 nm (20 °C), using an extinction coefficient (ε260) calculated with OligoAnalyzer 3.1 743 
(https://eu.idtdna.com/calc/analyzer). Heteroduplex substrates were prepared by heating the 744 
appropriate flap (or exo) strand with the complementary template in a 10:11 ratio at 95 °C for 745 
5 min in 100 mM KCl, 50 mM HEPES pH 7.5 with subsequent cooling to room temperature 746 
(Supplementary Table 6 and Supplementary Figure 5). 747 
 748 
Steady-state kinetic experiments – Reaction mixtures containing twelve different 749 
concentrations of FAM-labeled DF1 (Supplementary Figure 5a) substrate were prepared in 750 
reaction buffer (RB; 55 mM HEPES pH 7.5, 110 mM KCl, 80 mM MgCl2, 0.1 mg/mL bovine 751 
serum albumin, 1 mM DTT) and incubated at 37 °C for 10 min. Reactions were initiated by 752 
the addition of hFEN1-336Δ in RB. Reactions were sampled at seven time intervals between 753 
2–20 min and quenched with excess EDTA (250 mM) with reaction progress being monitored 754 
by dHPLC equipped with a fluorescence detector (Wave® fragment analysis system, 755 
Transgenomic UK) as described.32 All reactions were independently repeated four times. 756 
Initial rates (v0, nM min–1) were determined by linear regression of plots of the amount of 757 
product concentration versus time up to 10% product formation. Kinetic parameters kcat and 758 
KM were determined by generalized nonlinear least squares using a Michaelis–Menten model 759 
(Equation 1), from plots of normalized initial rates (v0/[E]0, min–1) as a function of substrate 760 
concentration. The error distribution was assumed to be Gaussian, but to account for the 761 
unequal variance with increasing substrate concentration the variance was weighted to 1/Y2. 762 
All graph fitting and statistical analyses were done using GraphPad Prism 6.04 (GraphPad 763 
Software, Inc.). 764 
Equation 1 765 
 766 
Inhibition Studies – The steady-state kinetic parameters of hFEN1-336Δ with DF1 were 767 
determined as above at various concentrations of 1, 2 and 4 (0, 5, 10, 50, 100, 500, 1000 nM) 768 
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diluted from DMSO stock solutions as required. For each inhibitor concentration, reactions 769 
were followed in triplicate (each replicate using an independent serial dilution of enzyme) at 770 
six different concentrations of DF1 (10, 50, 100, 500, 1000, 5000 nM). Each experiment was 771 
independently conducted twice in triplicate. RB was used with a final DMSO concentration of 772 
1% (this DMSO concentration did not affect reaction rates in the absence of inhibitor). 773 
Reactions were assayed, and normalized initial rates were determined, as described for 774 
steady-state analyses. Kinetic parameters kcat and KM were determined globally for the four 775 
simplest types of reversible linear inhibition: uncompetitive (Equation 2), competitive 776 
(Equation 3), non-competitive (Equation 4) and mixed (Equation 5) by non-linear regression 777 
plots of normalized initial rates (νo/[E]o, min-1) versus the substrate concentration for each 778 
concentration of inhibitor. The same weighting as above (1/Y2) was applied in each case. In 779 
addition to the goodness of fit of these calculated slopes to the raw normalized initial rates, 780 
statistical analyses were done using GraphPad Prism. Akaike information criteria (AIC) was 781 
employed as a statistical test to aid model selection (e.g. non-competitive versus competitive). 782 
Unless the more complex model gave a difference in AIC of more than –6 (95% probability), 783 
the less complex model was preferred as the appropriate one. This type of analysis penalizes 784 
the more parameterized model unless the sum-of-squares is significantly reduced. As an 785 
additional check, the residuals from both the non-competitive and mixed inhibition models 786 
were inspected. IC50 values for inhibition of hFEN1-336Δ by compounds 1, 2 and 4 (reported 787 
in Figure 2g) were derived from data obtained at 100 nM substrate DF1 and the same 788 
concentrations of inhibitor as above, using nonlinear regression in GraphPad Prism. 789 
  790 
29 
 
 791 
Equation 2 792 
 793 
Equation 3 794 
 795 
Equation 4 796 
 797 
Equation 5 798 
 799 
The rates of reaction of hFEN1-, hFEN1–PCNA-, hEXO1- and T5FEN-catalysed reactions of 800 
SF, DF4, EO and pY7 (Supplementary Tables 5,6 and Supplementary Figure 5h,i), 801 
respectively, were also determined at varying concentrations of compounds 1 and 4 (hFEN1–802 
PCNA), 1 and 2 (hEXO1) or 1 only (T5FEN) in an analogous fashion at fixed concentrations 803 
of substrate as detailed in Supplementary Figure 6b–e.  804 
 805 
RNA and DNA oligonucleotides used in XRN1 assays were ordered purified using reverse-806 
phase HPLC and synthesised by DNA Technology (Risskov, Denmark), using standard 807 
phosphoramidites. Reactions were performed as described,51 but were monitored by 808 
denaturing PAGE using a Chemidoc system (Bio-Rad) to visualize the FAM and TAMRA 809 
labelled oligos (Supplementary Figure 16). 810 
 811 
Human APE1 was purchased from Sino Biologicals via Life Technologies. APE1 was 812 
assayed with the AP1 substrate57 in 50 mM HEPES-KOH pH 7.5, 25 mM KCl, 5 mM MgCl2 813 
and 0.1 mg/mL BSA. The reaction was monitored by dHPLC in a manner analogus to FEN1.  814 
 815 
Determination of kSTmax of hFEN1, hFEN1-336Δ and hFEN1-R100A in the presence and 816 
absence of inhibitors – Maximal single turnover rates of reaction were determined using 817 
rapid quench apparatus, or manual sampling where appropriate, in triplicate (technical 818 
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replicates) at 37 °C as described.32 To initiate reaction, enzyme at a final concentration of at 819 
least 10 × Kd of the substrate (DF1; Supplementary Tables 56 and Supplementary Figure 5a) 820 
in RB was added to an equal volume of substrate in the same buffer. To determine kSTmax in 821 
the presence of the inhibitor 1 or 2, reaction mixtures were prepared as above but containing 822 
100 μM (1% DMSO) of either inhibitor. Samples were quenched (1.5 M NaOH, 80 mM 823 
EDTA) over a range of different time intervals and reaction progress monitored as above.32 824 
The first-order rate constant (kSTmax) of reaction was determined by plotting the appearance of 825 
product against time (Pt) and applying nonlinear regression to Equation 6, where P∞ is the 826 
amount of product at endpoint.  827 
 828 
Pt = P∞ (1–exp–kSTmax.t) Equation 6 829 
 830 
Fluorescence Anisotropy – Dissociation constants for free enzyme and the enzyme–inhibitor 831 
complex with the DNA substrate (DF1; Supplementary Tables 5,6 and Supplementary Figure 832 
5a) were measured under equilibrium conditions by fluorescence anisotropy using a Horiba 833 
Jobin Yvon FluoroMax-3® spectrofluorometer with automatic polarizers. The excitation 834 
wavelength was 490 nm (slit width 5 nm) with emission detected at 510 nm (slit width 5 nm). 835 
Samples contained 10 mM CaCl2 or 2 mM EDTA (or when inhibitors were present 8 mM 836 
MgCl2) and 10 nM DF1, 110 mM KCl, 55 mM HEPES pH 7.5, 0.1 mg/mL bovine serum 837 
albumin, 1 mM DTT and 1% DMSO. Inhibitors 1 and 2 were added at 100 µM as 838 
appropriate. This solution containing substrate was incubated at 37 °C for a minimum of 10 839 
min before the first measurement at 0 nM protein with subsequent readings taken on the 840 
cumulative addition of enzyme in a matched buffer, with corrections made for dilution. Data 841 
were modeled by nonlinear least squares regression in KaleidaGraph 4.0 using Equation 7, 842 
where r is the measured anisotropy at a particular total concentration of enzyme ([E]) and 843 
fluorescent substrate ([S]), with rmin giving the minimum anisotropy, of free DNA, and rmax the 844 
maximum anisotropy, the anisotropy of the saturated substrate. 845 
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 Equation 7 846 
The equilibrium dissociation constant Kd(binding) is extracted from this analysis. Each 847 
measurement was independently repeated in triplicate (Supplementary Figure 10), and 848 
samples were taken after completion of the titration and analyzed by dHPLC to determine the 849 
amount of product produced (Supplementary Figure 11a). 850 
 851 
Fluorescence Anisotropy Competition Experiments – Samples were prepared and anisotropy 852 
readings taken as described for the protein–DNA equilibrium binding measurements above. 853 
Enzyme was added cumulatively up to ~ 80% saturation of the substrate (DF1; 854 
Supplementary Tables 5,6 and Supplementary Figure 5a). At this point unlabeled DNA in the 855 
same buffer (DF2; Supplementary Table 5,6 and Supplementary Figure 5b) was added in a 856 
stepwise manner with readings taken after each addition of the competitor until the anisotropy 857 
value reached that of oligonucleotide in the absence of any protein (Supplementary Figure 858 
11h).  859 
 860 
Fluorescence Resonance Energy Transfer (FRET) – FRET energy transfer efficiencies (E) 861 
were determined using the (ratio)A method58 by measuring the enhanced acceptor 862 
fluorescence. The steady state fluorescent spectra of 10 nM non-labeled trimolecular, donor-863 
only labeled and doubly-labeled DNA substrates (Supplementary Figure 5c,d,f) were recorded 864 
using a Horiba Jobin Yvon FluoroMax-3® fluorometer and normalized for lamp and 865 
wavelength variations. For direct excitation of the donor (fluorescein, DOL) or acceptor 866 
(rhodamine, AOL; Supplementary Figure 5e), the sample was excited at 490 nm or 560 nm (2 867 
nm slit width) and the emission signal collected form 515–650 nm or 575–650 nm (5 nm slit 868 
width). Emission spectra were corrected for buffer and enzyme background signal by 869 
subtracting the signal form the non-labeled (NL) DNA sample. In addition to 10 nM of the 870 
appropriate DNA construct samples contained 10 mM CaCl2 or when inhibitor was present 8 871 
r = rmin +
(rmax - rmin)
2[S]
([S] + [E] + KD) - ([S] + [E] + KD)
2 - 4[S][E]
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mM MgCl2 or 2 mM EDTA and 110 mM KCl, 55 mM HEPES pH 7.5, 0.1 mg/mL bovine 872 
serum albumin, 1 mM DTT, 1% DMSO and 100 μM inhibitor 1 or 2 as appropriate. The first 873 
measurement was taken prior to the addition of protein (either hFEN1-WT or hFEN1-R100A) 874 
with subsequent readings taken on the cumulative addition of enzyme, with corrections made 875 
for dilution. Transfer efficiencies (E) were determined according to Equation 8, where FDA 876 
and FD represent the fluorescent signal of the doubly-labeled DNA (DAL) and donor-only-877 
labeled DNA (DOL) at the given wavelengths, respectively; εD and εA are the molar 878 
absorption coefficients of donor and acceptor at the given wavelengths; and εD(490)/εA(560) 879 
and εA(490)/εA(560) are determined from the absorbance spectra of doubly-labeled molecules 880 
(DAL) and the excitation spectra of singly rhodamine-only-labeled molecules (AOL). Energy 881 
transfer efficiency (E) was fit by non-linear regression to Equation 9, where Emin and Emax are 882 
the minima and maxima of energy transfers, [S] is the substrate concentration, [P] is the 883 
protein concentration and KD is the bending equilibrium dissociation constant of the protein 884 
substrate [PS] complex. 885 
 886 
 887 
 888 
 889 
 890 
Equation 8 891 
Equation 9      892 
 893 
2-Aminopurine Exciton-Coupled Circular Dichroism (ECCD) Spectroscopy – Spectra were 894 
recorded of samples containing 10 μM DF3 (Supplementary Figure 5g), 110 mM KCl, 55 895 
mM HEPES pH 7.5, 1 mM DTT and either 10 mM CaCl2; 10 mM CaCl2 + 25 mM EDTA; 8 896 
mM MgCl2 + 100 µM compound 1 or 2; or 8 mM MgCl2 + 100 µM compound 1 or 2 + 25 897 
mM EDTA; and, where appropriate, 12.5 μM protein, using a JASCO J-810 CD 898 
spectrophotometer (300–480 nm) at 20 °C as described.28 In samples containing either 899 
E=Emi n +
( Ema x -Emin)
2[S] ([S] + [P] + KD) -
([S] + [P] + KD)2 - 4[ S ][ P] 
N = FDA(λDEX,λDEM)/FD(λDEX,λDEM) 
(ratio)A = (FDA(λDEX,λAEM)-N.FD(λDEX,λAEM))/FDA(λAEX,λAEM)
E = (ratio)A/(εD(490)/εA(560))-(εA(490)/εA(560))
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inhibitor 1 or 2, the enzyme was pre-incubated with the inhibitor before addition of the 900 
substrate. The CD spectra were plotted as Δε per mol of 2AP residue versus wavelength. Each 901 
measurement was independently repeated (typically in triplicate) and gave similar results. 902 
After measurements were recorded aliquots were taken and the amount of product produced 903 
was checked by dHPLC (Supplementary Figure 12b). 904 
 905 
Differential Scanning Fluorimetry (DSF) – The stability of purified hFEN1 and hEXO1-352 906 
with and without available Mg2+ was assessed as a function of inhibitor concentration by 907 
DSF36 using the fluorescent probe SYPRO® Orange (Sigma–Aldrich). Final volumes of 20 μL 908 
containing 2.5 μM hFEN1 or hEXO1-352 in 50 mM HEPES–KOH pH 7.5, 100 mM KCl, 8 909 
mM MgCl2, 1× SYPRO® Orange with either 25 mM EDTA or 25 mM NaCl and various 910 
concentrations of compound 1 or 2 (0, 1, 2, 4, 6, 8, 10, 20, 40, 60, 80, 100 μM) were mixed in 911 
white 96-well PCR-plates (Starlab) and sealed with StarSeal Advanced Polyolefin Film 912 
(Starlab). The plates were inserted into an Agilent MX3005P QPCR instrument for thermal 913 
denaturation. The emission at 610 nm (excitation 492 nm) from each well was recorded from 914 
25 to 95 °C at a scan rate of 1 °C/min with a filter set gain multiplier of ×4. Analysis of the 915 
resulting thermal denaturation curves was accomplished using the DSF Analysis Excel36 916 
script as described (ftp://ftp.sgc.ox.ac.uk/pub/biophysics) in combination with GraphPad 917 
Prism 6.04, which provided the nonlinear regression function with the Boltzman equation 918 
(Equation 10).  919 
ܫ(ݔ) = ܫ଴ + ூభିூబ
ଵା௘൬
೅೘ష೅(ೣ)ೞ೗೚೛೐ ൰
  Equation 10 920 
 921 
Cellular Thermal Shift Assay (CETSA)  922 
CETSA was performed as described37 by first establishing melt curves and ligand-induced 923 
shifts followed by testing of the compounds with increasing concentrations of 1 or 4 at a 924 
single temperature to establish the CETSA EC50 of target engagement. Target engagement 925 
was determined by isothermal concentration–response (IsoT C–R) stabilization curves for 926 
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compound 1 and 4 on hFEN1 in treated intact cells. Western blots were performed using an 927 
iBlot2 device (Life Technologies) on nitrocellulose membranes. Transfer was set to 8 minutes 928 
at 25 V. Blocking and dilution of antibodies were performed in 5% non-fat milk in Tris 929 
Buffered Saline–Tween (TBST). A commercially available primary antibody against hFEN1 930 
(ab109132, Abcam) was diluted at 1:5000 and incubated at 4 °C overnight. Specific hFEN1 931 
bands were then detected using the horseradish peroxidase (HRP) conjugated secondary 932 
antibody sc-2374 (Santa Cruz Biotechnology) together with Clarity Western ECL substrate 933 
(BioRad).  934 
 935 
Melt and shift curves (Figure 5a,b) for FEN1 in intact SW-620 cells were determined by 936 
washing cells with HBSS followed by trypsinization using TrypLE (Gibco) and pelleting by 937 
centrifugation. The pellet was washed with HBSS, pelleted and re-suspended in HBSS to a 938 
cell density of 20 million cells/mL. Compound incubation was performed during 60 minutes 939 
at 37 °C at 100 μM final concentration, whereas 0.2% DMSO was used as negative control. 940 
The samples were gently mixed every 10 min. Cell viability was measured before and after 941 
compound incubation. The treated cells were divided into 50 μL aliquots and subjected to a 942 
12-step heat challenge between 37 and 70 °C for 3 min, followed by immediate cell lysis by 3 943 
rounds of freeze–thawing. Precipitated protein was pelleted by centrifugation at 20,000 g for 944 
20 min, then 30 μL of the supernatant was mixed with 15 μL gel loading buffer (NuPAGE 945 
LDS sample buffer, Life Technologies) and 10 μL/lane of the mixture was loaded to a gel. 946 
Protein amounts were detected using Western blot techniques as described above.  947 
 948 
Isothermal concentration response curves (Figure 5c) were determined with intact SW-620 949 
cells treated as above, but at a final concentration of 40 million cells/mL. The cell suspension 950 
was divided into 30 μL aliquots and an equal volume of HBSS containing 2× the intended 951 
compound concentration was added, resulting in a final cell concentration of 20 million 952 
cells/mL at the correct concentration. A 7-step dilution concentration response series of the 953 
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ligands in 0.2% DMSO was applied together with 0.2% DMSO as control. The log10 dilution 954 
series ranged from 100 pM to 100 μM. An additional 7-step series was applied, ranging from 955 
100 nM to 300 μM. The cells were incubated with ligand at 37 °C for 60 min, with gentle 956 
mixing every 10 min. The aliquots were heated to a single specific temperature, 50 °C, as 957 
determined from the previously established FEN1 melt and shift curves, for 3 min, and lysed 958 
by 3 cycles of freeze–thawing. Precipitated protein and cellular debris were pelleted by 959 
centrifugation at 20.000 g for 20 min then 40 μL of the supernatant was mixed with 20 μL 960 
LDS sample buffer. Protein amounts were detected after loading 10 μL/lane of the 961 
supernatant/LDS mixture per on a gel using standard Western blot techniques.  962 
 963 
The Western blot intensities were obtained by measuring the chemiluminescence counts per 964 
mm2 (I = count/mm2). The obtained intensities were plotted in GraphPad Prism for melt 965 
curves, with the luminescence count normalized to the control count at 37 °C. The IsoT C–R 966 
data was analyzed and normalized to the maximum compound concentration. The normalized 967 
intensities were plotted and analyzed using GraphPad Prism. Data points are shown as mean 968 
values with error bars indicating the standard error of the mean. Concentration–response 969 
curves were fitted using the modified logistic Hill equation algorithm included in the 970 
GraphPad Prism software. The obtained CETSA™ EC50 concentration response values 971 
represent the half maximal concentration of the ligands for stabilizing hFEN1 at 50 °C. The 972 
quoted EC50 with 95% confidence intervals is therefore a relative measure of target 973 
engagement of compound available for interaction with FEN1 in intact SW-620 cells. 974 
 975 
Cytotoxicity Assay – SW620 cells were obtained from ATCC and HeLa SilenciX cell lines 976 
stably expressing shRNA against Fen1, Rad54b or a non-targeting control were obtained from 977 
Tebu Biosciences. Cell-line identity was confimed by short tandem repeat fingerprinting prior 978 
to banking and cells are routinely tested for mycoplasma contamination. SilenciX gene 979 
knockdown was confirmed by quantitative PCR. Exponentially growing cells were split into 980 
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6-well plates at an appropriate density in Dulbecco’s Modified Eagle’s Medium (DMEM) 981 
supplemented with 2 mM L-glutamine and 10% foetal calf serum (FCS) and incubated for 24 982 
h to allow cells to adhere. Cells were treated with compound 1 or 4 (diluted from DMSO 983 
stock solution) at the concentration stated. For the MMS sensitivity assay, cells were pre-984 
treated with 100 μM MMS in DMEM for 2 h before replacing the media with DMEM 985 
containing the stated concentration of 1 or 4. For siRNA survival assays, Fen1 knockdown 986 
was achieved by treating with targeting and non-targeting siRNA pools (Dharmacon) for 24 h 987 
using RNAiMAX lipofectamine transfection reagent (Life Technologies) before cells were 988 
allowed to recover in fresh media. In all cases, plates were incubated for 10–14 days to allow 989 
for colony formation. Colonies were stained with crystal violet and colony frequencies 990 
determined using the GelCount automated system (Oxford Optronix). Survival is expressed as 991 
a percentage of a mock-treated control. Knockdown of Fen1 by siRNA was confirmed by 992 
Western blot. 993 
 994 
DNA Damage Induction Assay – Exponentially growing SW620 cells were seeded in 6-well 995 
plates and incubated for 4 days with compound 1 at the stated dose. Cells were subsequently 996 
washed, trypsinized and lysed in Cell Panel Lysis Buffer (5 mM Tris-HCl, 3 mM EDTA, 3 997 
mM EGTA, 50 mM NaF, 2 mM sodium orthovanadate, 0.27 M sucrose, 10 mM β-998 
glycerophosphate, 5 mM sodium pyrophosphate, and 0.5% Triton X-100) supplemented with 999 
complete protease and phosSTOP phosphotase inhibitors (both Roche). Proteins were 1000 
separated by gel electrophoresis and transferred to nitrocellulose membrane by Western blot. 1001 
Membranes were probed, at a concentration of 1:1000 unless stated otherwise, for cleaved 1002 
PARP (#9541, Cell Signaling Technology), γH2AX (#2577, Cell Signaling Technology; 1003 
1:500), GAPDH (#3683, Cell Signaling Technology; 1:5000), FEN1 (ab109132, Abcam), 1004 
phospho-ATM (Ser1981) (ab81292, Abcam), PARP (51-6639GR, BD Biosciences), ATM 1005 
(sc-23921, Santa Cruz Biotechnology) and FANCD2 (sc-20022, Santa Cruz Biotechnology). 1006 
 1007 
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Accession Codes – The PDB accession code for the X-ray crystal structure of compound 1 1008 
bound to human FEN1, as detailed above, is 5FV7. 1009 
 1010 
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